Innoviva, Inc. (NASDAQ: INVA), based in California, USA, is a forward-looking biopharmaceutical company committed to bringing transformative, innovative medical solutions to patients worldwide. The company is deeply embedded in the field of respiratory medication, primarily focusing on the successful commercialization of unique, patented therapies for chronic obstructive pulmonary disease (COPD) and asthma.
Initially founded in 1996 as Theravance, Innoviva was rebranded in 2016 to better reflect its strategic vision: breathing new life into pharmaceutical innovation. The company has a long track record of partnering with some of the leading global pharmaceutical and biotech companies, including GlaxoSmithKline (GSK), with whom Innoviva co-developed TRELEGY ELLIPTA, a once-daily, single inhaler triple therapy for COPD.
Innoviva's business model is unique. Rather than manufacturing and distributing therapies itself, Innoviva banks on its expertise in identifying, developing, and commercializing unique therapies sourced from global partners. The company then earns revenue through royalty payments received from these pharmaceutical partnerships.
Asides from TRELEGY ELLIPTA, its partnership with GSK has also given birth to other novel medicines that include RELVAR/BREO ELLIPTA, a once-daily combination of drugs to treat COPD and asthma, and ANORO ELLIPTA, another once-daily treatment for patients suffering from COPD.
Through the smart execution of its strategy, Innoviva continues to realize the value of its tremendous respiratory portfolio. The company has an impressive track record of transforming novel ideas into commercially successful therapies, reflecting its competitive edge in navigating the complex process of drug development through to commercialization.
Innoviva’s successful track record is further enhanced by its experienced management team comprised of accomplished leaders in the healthcare and pharmaceutical industries. Their combined wealth of knowledge and extensive industry relationships continuously drive the company's leadership in the development of novel treatments ensuring long-term value for its stakeholders.
Innoviva's business model and strategic alliances position it well to remain a significant contributor in the sphere of respiratory medication which contributes positively towards improving the quality of life for millions of patients globally.
Through decades of dynamic operations, Innoviva has successfully positioned itself as a global powerhouse in the commercialization of unique, cutting-edge respiratory solutions. Its commitment to continuous innovation and deep industry connections lay a solid foundation for potential growth and global impact in the years to come.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Aurigene Pharmaceutical Services Ltd., in collaboration with Dr. Reddy's Laboratories, Innoviva Specialty Therapeutics, and the Global Antibiotic Research & Development Partnership, received the CPHI Pharma Award 2026 in the True Partnership Excellence category. This award recognizes their joint efforts and integrated CRDMO model in addressing complex pharmaceutical development and manufacturing challenges for the Zoliflodacin Multiparty Partnership. Akhil Ravi, CEO of Aurigene, emphasized the importance of strong partnerships, technical excellence, and shared commitment to patients in advancing innovative medicines.
Heavy trading in Innoviva's Dec. 18, 2026 US$10.00 call options has raised questions about the stock's bull case, signaling potential major developments not yet public. Analysts project a decline in Innoviva's earnings by 2029 despite revenue growth, with a consensus price target of US$35.00 against a current share price of US$21.14. This options activity encourages investors to re-evaluate their expectations for the NUZOLVENCE rollout and other key growth drivers against the implied financial trajectory.
The article details precision trading strategies for Innoviva Inc. (INVA), highlighting a 30.7:1 risk-reward setup targeting an 8.9% gain with only 0.3% risk. It provides institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for different risk profiles and holding periods.
Zacks has identified Innoviva (INVA) as a strong value pick due to its A grade for Value and favorable P/E and cash flow metrics, despite mixed recent trading performance. The stock is considered 40% undervalued with a fair value of $35 per share, largely based on expected respiratory royalties and the potential contributions from Armata Pharmaceuticals and Nortiva Bio. Investors are encouraged to weigh both the bullish narrative, supported by long-term returns and future prospects, against risks like a recent net income decline.
The article analyzes Innoviva (INVA) stock from a value investing perspective, noting its strong Zacks Rank #2 (Buy) and an "A" grade for Value. It highlights key valuation metrics such as a low P/E ratio (10.12 vs. industry average 17.64), a favorable P/S ratio (3.46 vs. industry average 4.23), and an attractive P/CF ratio (20.06 vs. industry average 29.69). Based on these metrics and a strong earnings outlook, the article concludes that INVA appears to be an undervalued stock.